AIV-007 is under clinical development by AiViva BioPharma and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AIV-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AIV-007 is under development for the treatment of neovascular age-related macular degeneration, macular edema and benign prostatic hyperplasia. It is administered by intravitreal and intraprostatic route. It targets vascular endothelial growth factor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and transforming growth factor-beta 1. The drug candidate is developed based on JEL technology.
AiViva BioPharma overview
AiViva BioPharma (AiViva) is a clinical-stage biotech company that develops drug products with the potential to profoundly reduce the treatment burden for patients and physicians and which may transform current treatment paradigms. AiViva is headquartered in Newport Beach, California, the US.
For a complete picture of AIV-007’s drug-specific PTSR and LoA scores, buy the report here.